Search clinical trials for: AMD070

Total 24 results

AstraZeneca
Quotient Sciences

Completed

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Cardiovascular Diseases

United Kingdom
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

HIV Infections

United States
Genzyme, a Sanofi Company

Completed

A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus

HIV Infections | X4 Tropic Virus

United States, United Kingdom
AstraZeneca
AstraZeneca K.K.

Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (PURSUIT)

Dyslipidemia

Denmark, Hungary, Spain, United States, Japan, Czechia, Slovakia, Canada
NMD Pharma A/S

Recruiting

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy (SYNAPSE-SMA)

Spinal Muscular Atrophy

United States, Spain, Belgium, Denmark, Germany, Netherlands, Italy, Canada
Eli Lilly and Company
ARMO BioSciences

Completed

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 2)

Healthy Adult Subjects

United States
Eli Lilly and Company
ARMO BioSciences

No longer available

An Expanded Access Program for AM0010 (Pegilodecakin)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma
Eli Lilly and Company
ARMO BioSciences

Completed

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants (Willow 3)

Healthy

United States
Eli Lilly and Company
ARMO BioSciences

Completed

A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 1)

Healthy Adult Subjects

United States
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
X4 Pharmaceuticals

Completed

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

Australia, United States
AnaMar AB
Covance

Completed

A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
X4 Pharmaceuticals

Active, not recruiting

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

WHIM Syndrome

United States, Denmark, Australia, Austria, France, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Russian Federation, Spain, Turkey
Novartis Pharmaceuticals

Terminated

Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Completed

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (VIBRANT-HD)

Early Manifest Huntington Disease

Canada, Germany, France, Spain, Hungary
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 1)

Non Small Cell Lung Cancer

United States
X4 Pharmaceuticals

Completed

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma (X4P-001-MELA)

Melanoma

United States
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

HIV Infections

United States
Eli Lilly and Company
ARMO BioSciences

Terminated

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 2)

Non Small Cell Lung Cancer

United States
Center for International Blood and Marrow Transplant...
Sanofi; Genzyme, a Sanofi Company

Completed

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Hodgkin's Disease | Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member

United States
AstraZeneca

Completed

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

Dyslipidemia

United States
AstraZeneca
Parexel

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

Dyslipidemia

United States, United Kingdom
Eli Lilly and Company
ARMO BioSciences

Completed

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia)

Pancreatic Cancer

United States, Belgium, Spain, Poland, Korea, Republic of, Taiwan, Germany, Italy, France, United Kingdom, Austria, Australia, Canada
Eli Lilly and Company
ARMO BioSciences

Active, not recruiting

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Carcinoma | Solid Tumors | Colorectal Carcinoma | Pancreatic Carcinoma

United States

Search clinical trials for: AMD070

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations